Completed
PoC Study to Evaluate the Efficacy and Safety of Secukinumab 300 mg in Patients With Lichen Planus
NCT04300296
- Conditions
- Lichen Planus, Lichen Planus: Cutaneous Lichen Planus, Mucosal Lichen Planus and Lichen Planopilaris, Lichenoid Eruptions, +3 more
- Locations
-
- Novartis Investigative Site Birmingham, Alabama, United States
- Novartis Investigative Site Thousand Oaks, California, United States
- Novartis Investigative Site Cromwell, Connecticut, United States
- Novartis Investigative Site Jacksonville, Florida, United States